Roche Holding’s (OTC:RHHBY) Neuroscience Drugs Revenue rose from around $4.6 billion in 2019 to $5.5 billion in 2020. Trefis expects the metric to rise to almost $7 billion in 2021 and $7.4 billion in 2022.
Sales are being driven primarily by Ocrevus, a drug that is used to treat multiple sclerosis. Ocrevus has been one of Roche’s most successful launches, given the large size of the market for multiple sclerosis treatments.
We think the projected growth for Roche’s isn’t priced into the stock yet. We value Roche’s ADR at about $54 per share, a 13% premium over the current market price.